You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.
This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.
The primary objective of this Registry study is to evaluate the long-term safety and effectiveness of adalimumab in CD subjects who are treated as recommended in the product label.
The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
Subjects who are newly prescribed HUMIRA® (adalimumab) therapy (have never been treated with adalimumab) or who are participants in AbbVie sponsored investigational CD trials, are currently receiving adalimumab and for whom the treating physician has made the decision to continue with adalimumab therapy beyond the duration of the investigational trial.
Subjects who were participants in AbbVie sponsored investigational Crohn's disease trials, who have not had dose interruptions since the last dose of study drug, where the Investigator can provide source documentation of dosing information.
Subjects who are currently receiving adalimumab, as per the local approved label, who have not had dose interruptions since the induction dose of adalimumab where the Investigator can provide source documentation of dosing information.
Subjects willing to consent to data being collected and provided to AbbVie.
Subjects capable of and willing to give written informed consent and to comply with the requirements of the Registry study protocol.
To give you the best possible user experience, this site uses cookies and by continuing to use this site, you agree that this site saves them on your devices for analytics purposes and to remember your preferences. For more information, please read our terms of use and our Privacy policy.